Scleroderma lung disease

JJ Solomon, AL Olson, A Fischer, T Bull… - European respiratory …, 2013 - Eur Respiratory Soc
Systemic sclerosis (SSc) is a systemic autoimmune disease that is characterised by
endothelial dysfunction resulting in a small-vessel vasculopathy, fibroblast dysfunction with …

Manifestations of scleroderma pulmonary disease

OA Minai, RA Dweik, AC Arroliga - Clinics in chest medicine, 1998 - Elsevier
Scleroderma (also known as systemic sclerosis) is a disease of unknown cause
characterized by the synthesis and deposition of excessive extracellular matrix and vascular …

Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies

A Lescoat, D Roofeh, M Kuwana, R Lafyatis… - Clinical Reviews in …, 2023 - Springer
Systemic sclerosis is the rheumatic disease with the highest individual mortality. The severity
of the disease is determined by the extent of fibrotic changes to cutaneous and internal …

[HTML][HTML] State-of-the-art evidence in the treatment of systemic sclerosis

JE Pope, CP Denton, SR Johnson… - Nature Reviews …, 2023 - nature.com
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

PJ Clements, MD Roth, R Elashoff… - Annals of the …, 2007 - ard.bmj.com
Objectives: Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc). This
report examines the differences at baseline and over 12 months between patients with …

Management of systemic-sclerosis-associated interstitial lung disease

KC Silver, RM Silver - Rheumatic Disease Clinics, 2015 - rheumatic.theclinics.com
In the past 35 years, since the introduction of angiotensin-converting enzyme inhibitor
therapy as the first effective treatment of scleroderma renal crisis, SSc-ILD has become the …

Interstitial lung disease in scleroderma

SR Schoenfeld, FV Castelino - Rheumatic Disease Clinics, 2015 - rheumatic.theclinics.com
Systemic sclerosis (SSc) is a heterogeneous disease characterized by vasculopathy,
autoimmunity, and fibrosis, with multiorgan involvement and no known cure. Pulmonary …

New developments in scleroderma interstitial lung disease

KB Highland, RM Silver - Current opinion in rheumatology, 2005 - journals.lww.com
New Developments in Scleroderma Interstitial Lung Disease : Current Opinion in
Rheumatology New Developments in Scleroderma Interstitial Lung Disease : Current …

Interstitial lung disease in scleroderma

B White - Rheumatic Disease Clinics, 2003 - rheumatic.theclinics.com
The prevalence of pulmonary fibrosis in scleroderma varies from 25% to 90%, depending on
the ethnic background of the patients studied and the method that is used to identify …

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

G Sircar, RP Goswami, D Sircar, A Ghosh… - Rheumatology, 2018 - academic.oup.com
Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …